Qualitek Labs

About Qualitek Labs

Incorporated in May’2018 in New Delhi, Qualitek Labs is a NABL-accredited laboratory company providing testing, inspection, homologation, certification and consultancy services. Its coverage includes automotive, defence, food and agriculture, pharma and healthcare, metals and minerals, environment and water. The company describes its network as 10 owned labs and 6 labs operating under a Public Private Partnership model, providing pan-India coverage.

Business

Services span transportation and technology, food and life sciences, healthcare and skincare, natural resources, and environment and sustainability. Testing work includes EV batteries, food and pharmaceutical products, minerals, electrical and electronic equipment, and defence equipment. The company also offers vehicle and component homologation and certification consultancy through government-recognized testing authorities.

• Service model: The company describes a mix of contract testing, project-based validation and longer-term compliance partnerships, supported by a cloud-based Laboratory Information Management System.
• FY25 milestones: Work included drinking-water testing for the Ministry of Jal Shakti, coal testing empanelment with the Ministry of Coal, a dedicated VOC testing lab in Noida and a partnership for export homologation.

Industry

The note identifies regulatory requirements, quality standards, international trade and consumer demand for quality products as drivers for the testing, inspection and certification market. It cites a global TIC market size of $31.76 Bn. in 2024, estimated at $33.95 Bn. in 2025, and projects $61.9 Bn. in 2033, with a 6.9% CAGR for 2025 – 2033. Management estimates the Indian TIC market at $7.62 Bn. in 2024 and $14 Bn. by 2033; after adjusting for government labs and MNCs, the report estimates an addressable market of INR 30,000 Cr. for Qualitek Labs.

Investment Rationale

• Broad testing portfolio: The company serves multiple industries and reports compliance with Indian and international standards, with services ranging from automotive and EV battery testing to food, pharmaceutical and mineral testing.
• Growth record: From FY23 to FY25, the report gives three-year CAGRs of 91.5% for revenue, 75.2% for EBITDA and 61.5% for PAT.
• New labs and operating leverage: The company added 9 labs in the last 18 months. The report says these labs have annual revenue potential of INR 120 Cr. over the next 2-3 years, compared with INR 8.9 Cr. of H1FY26 revenue from them.
• Management guidance: Management guidance is for 2x revenue every 2 years and ~30% EBITDA margins till the company achieves INR 500 Cr. of topline.
• Industry demand: The report links growth prospects to stricter quality requirements and regulatory activity, and estimates an addressable market of INR 30,000 Cr. for the company.
• Expansion plans: The stated priorities include lab process outsourcing, geographic expansion and new testing capabilities, including semiconductor and automotive, pharma, food and infrastructure labs.

Qualitek Labs Key Financials

FY25 consolidated operating revenue was 70.2, EBITDA was 16.2 and PAT was 7.7. For H1-FY26, the historical financials table reports revenue of 54.2, EBITDA of 11.2 and PAT of 4.8. The report notes that established labs delivered EBITDA margins of 32%, while new labs incurred losses.

Valuation and Target Price

The valuation applies a target P/E range of 40.0x – 45.0x to FY27 PAT. The report presents an implied target price of INR 633 - 712 against a current market price of INR 335, and states potential upside of 89% to 113%. No formal Buy, Hold, Reduce or Sell recommendation is stated in the note.

INR 335.0/-

CMP

INR 633 - 712

Implied target price

FY27 PAT

89% to 113%

Potential upside

Peer Comparison

The listed-peer table compares Qualitek Labs with Choksi Labs. It reports Qualitek Labs’ FY25 revenue at 70.2 and EBITDA margin at 23.1%, against Choksi Labs’ revenue of 42 and EBITDA margin of 27.0%. The table lists three-year revenue, EBITDA and PAT CAGRs of 91.5%, 75.2% and 61.5% for Qualitek Labs, compared with 10.1%, 4.9% and (31.2%) for Choksi Labs.

Management

• Antaryami Nayak: The CEO is a qualified CA and previously served as Regional Finance Director at Bureau Veritas - CPS, with earlier roles at Titan and Avery Dennison.
• Kamal Grover: The Executive Director leads sales and business development. His previous roles include positions at Avery Dennison and Bureau Veritas.
• Alok Kumar Agarwal: The Non-Executive Director has over 27 years of professional experience in finance and taxation.
• Mangesh Bhosale: The Director has over 26 years of leadership experience and a Master’s degree in Mechanical & Automation Engineering.

Key Risks

• Competition and customer onboarding: The TIC sector includes government labs, MNCs and smaller players. The report notes customer onboarding cycles can be long, including because some customers prefer MNC testing labels.
• Capital requirements and debt: Adding labs organically or through acquisitions requires continuing capex. The report cites debt of ~INR 72 Cr. as on Sep’25 and a Debt to Equity ratio of 0.51x.
• New labs have yet to break even: Nine new labs incurred an EBITDA loss of INR 3.3 Cr. in H1FY26. The report cites a minimum gestation period of 2-3 years for new labs to breakeven.

Our View

The thesis combines a diversified testing platform and strong reported growth with the prospect of newer labs contributing more as they mature. The key execution questions are whether these labs can reach breakeven and whether growth can be achieved while managing the capital needs. The report gives an implied target range of INR 633 - 712 and potential upside of 89% to 113%, but does not state a formal stock rating.

Standard disclosures

• Research Analyst has served as an officer, director or employee of subject company(ies): No
• We or our associates have received compensation from the subject company(ies) in the past 12 months: No
• We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
• We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months –No
• We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report –No
• We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- No
• Nature of financial interest in subject company, if any –Nil
• We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report – No
• Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report-No.
• We or our Associates or Research Analyst are engaged in market making of subject company – No
• By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
• There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.

Regulatory disclosures

Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).

Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.

The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness.

The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.

For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in or guptanishant.iimi@gmail.com| Contact Number: 8171433387 | Website: www.mcapital.in | Twitter: @Mcapital_In

Rating rationale

Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst’s valuation for a stock.

• Buy:> 15%
• Hold: -5% to 15%
• Reduce: -15% to -5%
• Sell: <-15%